Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02809716
Other study ID # 3C-15-4
Secondary ID NCI-2016-007363C
Status Completed
Phase
First received
Last updated
Start date August 1, 2016
Est. completion date May 29, 2020

Study information

Verified date August 2023
Source University of Southern California
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This research clinical trial studies high definition single cell analysis in blood and tissue samples from patients with colorectal cancer which has spread to the liver. High definition single cell analysis allows doctors to study the properties of cancer cells that are sometimes found in the blood of patients and to determine how the genes and proteins in them may change over time. Studying samples from patients with colorectal cancer in the laboratory may help doctors learn more about how cancer spreads, as well as how to predict the disease outcomes in patients with cancer.


Description:

PRIMARY OBJECTIVES: I. To determine the level of correlation between solid tumor touch preparations and liquid biopsies (circulating tumor cells [CTCs]) from patients with surgically resected colorectal cancer (CRC) metastases to the liver using single-cell high-content analysis, including gene copy number variation (CNV) and to establish one or more bio-signatures that represent the liquid and solid biopsy correlation for each patient and for the patient population. SECONDARY OBJECTIVES: I. To demonstrate the technical validity and reproducibility of the bio-signatures by comparing the two pre-resection liquid biopsy samples drawn one week prior to and on the day of surgery. TERTIARY OBJECTIVES: I. Compare biosignatures between pre-surgical and post-surgical blood samples. II. Compare biosignatures between resected metastatic liver tumor tissue, primary colon tumor tissue (if available), and pre-surgical blood samples. III. Compare biosignatures between blood samples prior to resection with those obtained after resection and at the time of recurrence. OUTLINE: Patients undergo blood collection 1 week prior surgery, before and after surgery on the same day, and 1 week and 3 months after surgery. Patients also undergo tissue collection during the surgery. Blood and tissue samples are processed for high definition single cell analysis including whole-genome CNV profiles, protein expression, and cell morphology. After completion of study, patients are followed up for up to 2 years.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date May 29, 2020
Est. primary completion date May 29, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Able to provide informed consent - Metastatic colorectal adenocarcinoma to the liver (hepatic mCRC) - Synchronous or metachronous - Solitary or multifocal - Concurrent abdominal lymph node metastasis is allowable - Hepatic mCRC deemed surgically resectable by the study team with plans to undergo surgery - Has not received any systemic chemotherapy for at least 21 days prior to scheduled hepatic resection Exclusion Criteria: - Non-adenocarcinoma metastatic colorectal cancer (e.g. neuroendocrine carcinoma); mucinous component is permitted - Metastatic CRC that involves organ(s)/tissue(s) other than abdominal lymph nodes and/or liver - Has received any systemic chemotherapy within 21 days prior to scheduled hepatic resection

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Biomarker Analysis
Correlative studies
Cytology Specimen Collection Procedure
Undergo collection of blood and tissue samples

Locations

Country Name City State
United States Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Houston Texas
United States Scripps Cancer Center La Jolla California
United States Los Angeles County-USC Medical Center Los Angeles California
United States USC / Norris Comprehensive Cancer Center Los Angeles California
United States Hoag Memorial Hospital Presbyterian Newport Beach California
United States USC Norris Oncology/Hematology-Newport Beach Newport Beach California

Sponsors (2)

Lead Sponsor Collaborator
University of Southern California National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary HD-SCA liquid biopsy biosignatures assessed by cell morphology, protein expression, and whole genome CNV profiles Biosignatures will be compared between cells from tumor tissue within the same patient, cells from blood samples within the same patient, cells from tumor tissue and blood samples within the same patient, cells from tumor tissue and blood samples across different patients. Upon these comparisons, biosignatures will be established which represent liquid and solid biopsy correlations for each patient and for the patient population. Descriptive statistics will be used to determine means, correlations, and variability of biosignatures between different specimens and time points, and within and acr Up to 2 years
Primary HD-SCA solid tumor biosignatures assessed by cell morphology, protein expression, and whole genome CNV profiles Biosignatures will be compared between cells from tumor tissue within the same patient, cells from blood samples within the same patient, cells from tumor tissue and blood samples within the same patient, cells from tumor tissue and blood samples across different patients. Upon these comparisons, biosignatures will be established which represent liquid and solid biopsy correlations for each patient and for the patient population. Descriptive statistics will be used to determine means, correlations, and variability of biosignatures between different specimens and time points, and within and acr Up to 2 years
Secondary HD-SCA biosignatures in pre-resection liquid biopsy samples assessed by cell morphology, protein expression, and whole genome CNV profiles The technical validity and reproducibility of the biosignatures will be demonstrated by comparing two pre-resection liquid biopsy samples. This reflects a change in the timing of specimen collection from the original protocol. Descriptive statistics will be used to determine means, correlations, and variability of biosignatures between different specimens and time points, and within and across patients. Up to day 1 of surgery
See also
  Status Clinical Trial Phase
Completed NCT01704703 - Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques Phase 2
Terminated NCT02960282 - Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy
Completed NCT01998152 - Individualized Nutritional Counselling During Chemotherapy for Colorectal Cancer (COLONUT) N/A
Not yet recruiting NCT06287723 - French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)
Completed NCT03005002 - Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver Phase 1
Completed NCT03095781 - Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Phase 1
Terminated NCT03111823 - Exercise Program During Chemotherapy in Metastatic Colorectal Cancer N/A
Active, not recruiting NCT04267575 - Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites N/A
Recruiting NCT03368963 - TAS102 in Combination With NAL-IRI in Advanced GI Cancers Phase 1/Phase 2
Active, not recruiting NCT04670445 - Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer N/A
Active, not recruiting NCT01271582 - Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients Phase 4
Active, not recruiting NCT03800602 - Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer Phase 2
Recruiting NCT05631574 - Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer Phase 1
Completed NCT03112668 - Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners N/A
Terminated NCT01550510 - Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA Phase 1/Phase 2
Recruiting NCT02919644 - Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer. Phase 2
Completed NCT03373188 - VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer Phase 1
Terminated NCT04044430 - Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer Phase 1
Completed NCT05025748 - Ask Questions (ASQ):Implementation of a Communication Intervention N/A
Completed NCT01722903 - Detection of CTCs in Patients Undergoing Surgery for Stage IV Colorectal Cancer N/A